Showing results (31-40 of 74) with videos related to
Sort By:
Pageof 8
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.The Pediatric Infectious Disease Journal|May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialKeith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.International Journal of Cancer|November 15, 2007
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American womenGonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, et al.Vaccine|July 13, 2004
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccineDarron R Brown, Kenneth H Fife, Cosette M Wheeler, et al.Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.The Lancet. Gastroenterology & Hepatology|June 4, 2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialAnnette Bruchfeld, David Roth, Paul Martin, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.Annals of Internal Medicine|April 25, 2015
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized TrialStefan Zeuzem, Reem Ghalib, K Rajender Reddy, et al.Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18Dennis Dias, Jeff Van Doren, Sonela Schlottmann, et al.Pageof 8